Intra-Cellular Therapies (ITCI) PT Raised to $38 at BTIG
BTIG raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $38.00 (from $36.00) while maintaining a Buy rating.
BTIG raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $38.00 (from $36.00) while maintaining a Buy rating.